Pemetrexed, sold under brand name Alimta by Eli Lilly and Company is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Alimta is a folate analog metabolic inhibitor and in combinations with certain drugs it is indicated for various diseases:
Global pemetrexed market size was valued at US$ 2,287.2 Million in 2022 and is expected to witness a CAGR of 2.2% over the forecast period (2022 – 2030).
Figure 1.Global Pemetrexed Market Share (%), by Distribution Channel, 2022
Increasing demand of hospital pharmacies due to 340b program boosts the growth of the market over the forecast period.
Increase in the demand of hospital pharmacies due to 340b program (Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients) drives the growth of the market over the forecast period. For instance, in November 2021, according to the reports published in Science direct, an online publishing database, reported that 340b hospitals provided a significantly higher average number of medication access services compared to non-340B hospitals, whereas a higher percentage of 340B hospitals reported providing the service compared to non-340B hospitals in the U.S. These services are known to improve access and quality of care for low income populations.
|Base Year:||2021||Market Size in 2022:||US$ 2,287.2 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||2.2%||2030 Value Projection:||US$ 2,728.1 Mn|
Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc.
|Restraints & Challenges:||
Figure 2. Pemetrexed Market Share (%), by Region, 2022
North America is expected to hold dominant position, owing to high prevalence of non-small cell lung cancer in the U.S
Increasing number of prevalence of non-small cell lung cancer in the U.S. drives the global pemetrexed market over the forecast period. For instance, American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) had been diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC, Non-small Cell Lung, (68%), stage IIIA NSCLC, Non-small Cell Lung Cancer (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%).
Global Pemetrexed Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals.
Increasing termination on ongoing clinical trials during covid-19 in oncology department hindered the growth of global pemetrexed market. For instance, in July 2020, according to the reports published by The European Federation of Pharmaceutical Industries and Associations, a trade association and lobbying organization, over 20% of global oncology trials were halted because of the pandemic, with breast, prostate and lung cancer trials impacted the most.
Moreover, in March 2020, the National Institute for Health Research (NIHR) in the U.K. decided to prioritize COVID-19 related trials and paused all other new or ongoing trials, as well as non-COVID laboratory-based medical research.
Global Pemetrexed Market: Key Developments
Global Pemetrexed Market: Restraints
Parenteral route of administration has to be performed under medical supervision, to avoid side effects and complications, which burdens cost on patients. The incorrect use of this therapy from parenteral route can cause liver dysfunction, refeeding syndrome, and other side effects.
Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc.
Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by US FDA (Food and Drug Administration) in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. As a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous (non-small cell lung cancer) NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. It is a single agent for the treatment of patients with recurrent, metastatic non-squamous (non-small cell lung cancer) NSCLC after prior chemotherapy.
Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to drive global pemetrexed market growth over the forecast period. For instance, in July 2018, STADAPHARM GmbH, an international pharmaceutical company the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe. The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta by Lilly. The launch helped the company in further expansion in pharmaceutical sector.
High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for pemetrexed drive global pemetrexed market growth over the forecast period. For instance, according to the data published by American Society of Clinical Oncology, an oncology organization, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.
Furthermore, key players in the market are dedicated to expand the indication of its pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company, a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients